Extensive-stage small-cell lung cancer

Alexander Spira; David S. Ettinger

doi:10.1002/ssu.10034

Extensive-stage small-cell lung cancer

Alexander Spira, David S. Ettinger

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Extensive-stage small-cell lung cancer (ES-SCLC) continues to be a difficult management issue. While response rates to therapy are relatively high, durable responses are rare, and long-term survival rates are dismal. Although many attempts have been made to develop new therapies, cisplatin-based combination chemotherapy remains the mainstay in the management of these patients. In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment.

Original language	English (US)
Pages (from-to)	164-175
Number of pages	12
Journal	Seminars in surgical oncology
Volume	21
Issue number	3
DOIs	https://doi.org/10.1002/ssu.10034
State	Published - Oct 22 2003

Keywords

Cisplatin
Etopiside
Small-cell lung cancer
Topotecan

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/ssu.10034

Cite this

@article{68cc44d84c50465e8ec5d3e44a1f9468,

title = "Extensive-stage small-cell lung cancer",

abstract = "Extensive-stage small-cell lung cancer (ES-SCLC) continues to be a difficult management issue. While response rates to therapy are relatively high, durable responses are rare, and long-term survival rates are dismal. Although many attempts have been made to develop new therapies, cisplatin-based combination chemotherapy remains the mainstay in the management of these patients. In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment.",

keywords = "Cisplatin, Etopiside, Small-cell lung cancer, Topotecan",

author = "Alexander Spira and Ettinger, {David S.}",

year = "2003",

month = oct,

day = "22",

doi = "10.1002/ssu.10034",

language = "English (US)",

volume = "21",

pages = "164--175",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Extensive-stage small-cell lung cancer

AU - Spira, Alexander

AU - Ettinger, David S.

PY - 2003/10/22

Y1 - 2003/10/22

N2 - Extensive-stage small-cell lung cancer (ES-SCLC) continues to be a difficult management issue. While response rates to therapy are relatively high, durable responses are rare, and long-term survival rates are dismal. Although many attempts have been made to develop new therapies, cisplatin-based combination chemotherapy remains the mainstay in the management of these patients. In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment.

AB - Extensive-stage small-cell lung cancer (ES-SCLC) continues to be a difficult management issue. While response rates to therapy are relatively high, durable responses are rare, and long-term survival rates are dismal. Although many attempts have been made to develop new therapies, cisplatin-based combination chemotherapy remains the mainstay in the management of these patients. In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment.

KW - Cisplatin

KW - Etopiside

KW - Small-cell lung cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0141928688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141928688&partnerID=8YFLogxK

U2 - 10.1002/ssu.10034

DO - 10.1002/ssu.10034

M3 - Review article

C2 - 14508849

AN - SCOPUS:0141928688

VL - 21

SP - 164

EP - 175

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -

Extensive-stage small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this